MedTrace Logo

Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine

NCT02762045 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-05-04

No results posted yet for this study

Summary

This is a randomized, double-blind placebo-controlled dose-escalation clinical trial to evaluate the safety and the immunogenicity of Adenoviral vector 5 HIV-1 vaccines in subjects receiving stable highly active antiretroviral therapy(HAART) .

Conditions

  • Acquired Immunodeficiency Syndrome

Interventions

BIOLOGICAL

Ad5-gag

Ad5-gag is used as vaccine in all arms.

BIOLOGICAL

Placebo

Preservation Solution is used as control in all arms.

Sponsors & Collaborators

  • Beijing Ditan Hospital

    collaborator OTHER

  • National Institutes for Food and Drug Control, China

    collaborator OTHER

  • Centers for Disease Control and Prevention, China

    lead OTHER_GOV

Principal Investigators

  • Yi Zeng, M.D. · National Institute for Viral Disease Control and Prevention, China CDC

  • Xia Feng, M.D. Ph.D · National Institute for Viral Disease Control and Prevention, China CDC

  • Ke Xu, Ph.D · National Institute for Viral Disease Control and Prevention, China CDC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02762045 on ClinicalTrials.gov